FR2143564A1 - Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates - Google Patents

Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates

Info

Publication number
FR2143564A1
FR2143564A1 FR7123703A FR7123703A FR2143564A1 FR 2143564 A1 FR2143564 A1 FR 2143564A1 FR 7123703 A FR7123703 A FR 7123703A FR 7123703 A FR7123703 A FR 7123703A FR 2143564 A1 FR2143564 A1 FR 2143564A1
Authority
FR
France
Prior art keywords
dressing
skin
long term
active materials
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7123703A
Other languages
English (en)
French (fr)
Other versions
FR2143564B1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US00042786A priority Critical patent/US3854480A/en
Priority claimed from ZA714095A external-priority patent/ZA714095B/xx
Application filed by Alza Corp filed Critical Alza Corp
Priority to FR7123703A priority patent/FR2143564A1/fr
Priority to DE2135533A priority patent/DE2135533C3/de
Priority to AT626171A priority patent/AT334545B/de
Priority to CH1062271A priority patent/CH574742A5/xx
Publication of FR2143564A1 publication Critical patent/FR2143564A1/fr
Application granted granted Critical
Publication of FR2143564B1 publication Critical patent/FR2143564B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
FR7123703A 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates Granted FR2143564A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US00042786A US3854480A (en) 1969-04-01 1970-06-02 Drug-delivery system
FR7123703A FR2143564A1 (en) 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates
DE2135533A DE2135533C3 (de) 1969-04-01 1971-07-15 Haftverband mit Reservoirschicht zur Aufnahme von systemisch wirksamen Arzneimitteln
AT626171A AT334545B (de) 1969-04-01 1971-07-19 Medizinischer verband
CH1062271A CH574742A5 (enExample) 1969-04-01 1971-07-19

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81211669A 1969-04-01 1969-04-01
US00042786A US3854480A (en) 1969-04-01 1970-06-02 Drug-delivery system
ZA714095A ZA714095B (en) 1969-04-01 1971-06-22 Bandage for administering drugs
FR7123703A FR2143564A1 (en) 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates

Publications (2)

Publication Number Publication Date
FR2143564A1 true FR2143564A1 (en) 1973-02-09
FR2143564B1 FR2143564B1 (enExample) 1974-04-05

Family

ID=37734020

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7123703A Granted FR2143564A1 (en) 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates

Country Status (4)

Country Link
US (1) US3854480A (enExample)
CH (1) CH574742A5 (enExample)
DE (1) DE2135533C3 (enExample)
FR (1) FR2143564A1 (enExample)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368962A1 (fr) * 1976-11-02 1978-05-26 Merck Patent Gmbh Pansement anti-bacterien et son procede de fabrication
FR2397190A1 (fr) * 1977-07-12 1979-02-09 Alza Corp Moyen pour l'administration de medicaments a travers la peau
FR2512651A1 (fr) * 1981-06-24 1983-03-18 Pere Lahaille Jeanne Produits anti-rides
EP0062682A4 (en) * 1980-10-20 1983-09-20 Nichiban Kk ADHESIVE PREPARATION FOR HEART DISEASES AND PROCESS FOR PREPARING THE SAME.
FR2534140A1 (fr) * 1982-10-12 1984-04-13 Fournier Laboratoires Nouveau dispositif pour l'administration percutanee de medicaments
FR2538247A1 (fr) * 1982-12-23 1984-06-29 Pere Lahaille Jeanne Pastille anti-rides et/ou traitant la peau
FR2548021A1 (fr) * 1983-06-29 1985-01-04 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
EP0151989A3 (en) * 1984-01-28 1986-10-08 Roshdy Dr. Ismail Means for the treatment of cardiac diseases
FR2581314A1 (fr) * 1985-05-03 1986-11-07 Alza Corp Dispositif medical pour l'administration transdermique de medicaments fortement ionises insolubles dans les corps gras
EP0262422A1 (en) * 1986-09-01 1988-04-06 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
EP0274863A3 (en) * 1987-01-09 1989-11-02 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
EP0344840A3 (en) * 1988-06-02 1990-02-21 Merck & Co. Inc. Transdermal delivery systems
US5322695A (en) * 1987-01-09 1994-06-21 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
WO1996031201A1 (en) * 1995-04-06 1996-10-10 Janssen Pharmaceutica N.V. Rate-controlled transdermal administration of risperidone

Families Citing this family (596)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4016251A (en) * 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4014987A (en) * 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4460367A (en) * 1977-06-09 1984-07-17 Alza Corporation Device containing biocide producing paraformalde and an acid
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
EP0009517A1 (en) * 1978-10-04 1980-04-16 THE PROCTER & GAMBLE COMPANY Vaginal contraceptive
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4382441A (en) * 1978-12-06 1983-05-10 Svedman Paul Device for treating tissues, for example skin
US4237888A (en) * 1979-03-23 1980-12-09 The Upjohn Company Two-membrane medicated device for rate-controlled administration of prostaglandins
EP0018097B1 (en) * 1979-03-23 1984-07-25 The Upjohn Company Medicated device for controlled drug release
US4308867A (en) * 1979-03-23 1982-01-05 Roseman Theodore J Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals
EP0021504B1 (en) * 1979-06-25 1984-10-03 THE PROCTER & GAMBLE COMPANY Article for use as catheter or the like
US4392848A (en) * 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4479795A (en) * 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
RO86519B (ro) * 1979-09-12 1985-03-31 Eli Lilly And Company Dispozitiv pentru rumegatoare
US4326510A (en) * 1979-11-20 1982-04-27 World Health Organization Barrier contraceptive torus
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4709996A (en) * 1982-09-30 1987-12-01 Michelson Paul E Fluid lens
CA1206049A (en) * 1982-09-30 1986-06-17 Paul E. Michelson Osmotic device for physiological applications
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4623329A (en) * 1983-12-15 1986-11-18 The Procter & Gamble Company Drainage and infusion catheters having a capillary sleeve forming a reservoir for a fluid antimicrobial agent
DE3505536C2 (de) * 1984-03-07 1994-08-04 Holz Wolfgang Verfahren und Arzneimittelbehälter zur Verarbreichung von Medikamenten o.dgl. an in Wasserbehältern gehaltene Tiere, insbesondere Fische
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4618487A (en) * 1984-07-06 1986-10-21 Alza Corporation Device for administering calcium ascorbate
DE3447833A1 (de) * 1984-12-29 1986-07-10 Allan Gerhard 8047 Karlsfeld Frühauf Tuch o.dgl. mit einen wirkstoff enthaltenden mikrokapseln
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
US6117448A (en) * 1986-08-28 2000-09-12 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
US5820876A (en) 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6126963A (en) 1986-08-28 2000-10-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
DE3823070A1 (de) * 1988-07-07 1990-02-22 Kettelhack Riker Pharma Gmbh Selbstklebendes heftpflaster
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
DE3844247A1 (de) * 1988-12-29 1990-07-12 Minnesota Mining & Mfg Vorrichtung, insbesondere pflaster zum transdermalen verabreichen eines medikaments
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648143B1 (fr) * 1989-06-08 1991-09-06 Rhone Poulenc Chimie Composition comprenant un copolymere silicone thermoplastique et un compose de l'iode, utilisable apres sa mise en forme, pour le traitement des eaux
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
US6264638B1 (en) 1989-12-07 2001-07-24 Ultrafem, Inc. Intravaginal drug delivery system and discharge collection device
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
DE69133077T2 (de) * 1990-06-01 2002-11-07 The Population Council, New York Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
WO1992022292A1 (de) 1991-06-10 1992-12-23 Schwarz Pharma Ag Nitroglycerin-pflaster und verfahren zu seiner herstellung
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5827245A (en) * 1992-07-16 1998-10-27 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising the active subtance 17-β-Estradiol (Anhydrous)
DE4223360C1 (enExample) * 1992-07-16 1993-04-08 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4328217C2 (de) * 1993-08-21 1996-01-11 Lohmann Therapie Syst Lts Therapeutisches System zur Behandlung der Psoriasis
EP0726749B1 (en) * 1993-11-03 2004-08-11 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
KR20000022465A (ko) 1996-07-03 2000-04-25 세바스티안 레슬리 제이. 탄성중합체 물질을 제작하기 위한 방법 및장치.
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
EP1003501B9 (en) 1997-04-02 2005-06-08 The Brigham And Women's Hospital, Inc. Use of an agent for lowering the risk of cardiovascular disease
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
ATE335510T1 (de) 1998-05-22 2006-09-15 Ottawa Health Research Inst Methoden und produkte zur induzierung mukosaler immunität
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
JP5490341B2 (ja) 1998-07-15 2014-05-14 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染のための多糖ワクチン
US6056976A (en) * 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
DE69939553D1 (de) 1998-12-30 2008-10-23 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DE19912477A1 (de) * 1999-03-19 2000-09-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System und Verfahren zu seiner Herstellung
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
AU776773B2 (en) 1999-05-05 2004-09-23 Cubist Pharmaceuticals, Inc. Novel catechols as antimicrobial agents
AU769652B2 (en) 1999-05-05 2004-01-29 Cubist Pharmaceuticals, Inc. Novel prolines as antimicrobial agents
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
PL197492B1 (pl) 1999-07-02 2008-04-30 Lohmann Therapie Syst Lts Transdermalny system terapeutyczny zawierający warstwę polimerową z zawartymi w niej mikrozbiornikami i sposób wytwarzania błon
EP2267029B1 (en) 1999-09-03 2016-06-15 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
US6376242B1 (en) * 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
DE19949202A1 (de) * 1999-10-13 2001-05-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure
DE19949252B4 (de) * 1999-10-13 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung
US6911525B2 (en) 1999-12-15 2005-06-28 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7534772B2 (en) 2000-06-22 2009-05-19 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
US7858331B2 (en) * 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
US7459287B2 (en) 2004-01-30 2008-12-02 Dana Farber Cancer Institute, Inc. Method for determination and quantification of radiation or genotoxin exposure
JP4564714B2 (ja) * 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
AU2002246688A1 (en) 2000-12-18 2002-07-30 Altus Biologics Inc. Methods for preparing purified daptomycin
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7923055B2 (en) * 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
DK1455593T3 (da) 2001-10-06 2013-08-26 Merial Ltd Fremgangsmåder og sammensætninger til fremme af vækst og medfødt immunitet hos unge dyr
AU2002340662B2 (en) * 2001-11-07 2008-07-03 Tekmira Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
WO2003078960A2 (en) * 2002-03-11 2003-09-25 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
AU2003220222A1 (en) 2002-03-13 2003-09-29 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
JP4913588B2 (ja) * 2003-01-21 2012-04-11 タリオン ファーマシューティカルズ インク． ファルネシルベンゾジアゼピノンの製造方法及び薬剤としての使用
US7358241B2 (en) * 2003-01-21 2008-04-15 Thallion Pharmaceuticals, Inc. Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
WO2004065401A1 (en) * 2003-01-21 2004-08-05 Ecopia Biosciences Inc. Polyene polyketides, processes for their production and their use as a pharmaceutical
DE102004002243A1 (de) * 2003-02-07 2004-09-16 Trikon Technologies Limited, Newport Elektrostatische Klemmhalterung für dünne Wafer in einer Vakuumkammer zur Plasmabearbeitung
US8227212B2 (en) 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
JP2006523226A (ja) 2003-02-28 2006-10-12 ザ ジョンズ ホプキンス ユニバーシティ Ｔ細胞調節方法
WO2004078943A2 (en) * 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
WO2005019819A1 (en) 2003-08-20 2005-03-03 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
CA2467249C (en) * 2003-05-13 2005-03-22 Ecopia Biosciences Inc. Polyene polyketides, processes for their production and their use as pharmaceuticals
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
EP1633352B1 (en) * 2003-06-13 2006-11-02 Ecopia Biosciences Inc. Polyene oxazoles with antitumour activity and processes for their preparation using a streptomyces strain
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
WO2005027714A2 (en) 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
WO2005024025A1 (en) * 2003-09-11 2005-03-17 Ecopia Biosciences Inc. Polyene polyketides and methods of production
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
CA2558667A1 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Antisense oligonucleotides for inhibiting the formation of metastases in cancer
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7504086B2 (en) * 2004-03-31 2009-03-17 Canon Kabushiki Kaisha Structure and method for releasing substance therefrom
DK1745075T3 (da) 2004-04-21 2013-06-24 Brigham & Womens Hospital Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
EP1629844B2 (en) 2004-07-13 2012-04-18 Bayer Schering Pharma Oy A longterm delivery system with controlled initial burst
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
US7893034B2 (en) 2004-09-02 2011-02-22 Yale University Regulation of oncogenes by microRNAs
JP5635726B2 (ja) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション 癌の診断方法及び治療方法
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
WO2006047891A1 (en) * 2004-11-08 2006-05-11 Ecopia Biosciences Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
EP1817056B1 (en) 2004-11-11 2014-08-13 The General Hospital Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
TWI436991B (zh) 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
BRPI0608818A2 (pt) 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
KR20070122563A (ko) 2005-04-19 2007-12-31 일라이 릴리 앤드 캄파니 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
AU2006243218B2 (en) 2005-05-05 2009-09-17 Antisense Pharma Gmbh Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors
US7763604B2 (en) * 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CA2547866C (en) * 2005-06-02 2008-08-12 Ecopia Biosciences Inc. Farnesyl dibenzodiazepinone formulation
CN101198324B (zh) * 2005-06-16 2011-06-08 欧洲凯尔特公司 用于改进剂型的大麻素活性药物成分
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CN101228188A (zh) 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
DK1906972T3 (da) 2005-07-19 2013-12-16 Univ Tennessee Res Foundation LPA2-receptoragonist til behandling af diarré
EP1909812A4 (en) 2005-07-27 2009-11-25 Univ Florida SMALL CONNECTIONS FOR THE CORRECTION OF PROTEIN MISFAIRINGS AND USES THEREOF
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
DK1933810T3 (da) * 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
US20100003297A1 (en) 2005-08-11 2010-01-07 Massachusetts Institute Of Technology Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
WO2007027559A2 (en) 2005-08-29 2007-03-08 Shashoua Victor E Neuroprotective and neurorestorative methods and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US20080280834A1 (en) * 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US20090325944A1 (en) * 2006-04-12 2009-12-31 Suzanne Walker Kahne Methods and Compositions for Modulating Glycosylation
KR101141333B1 (ko) 2006-06-20 2012-05-23 트랜스진 에스.에이. 재조합 바이러스 백신
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049563B1 (en) * 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20100092480A1 (en) * 2006-10-13 2010-04-15 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
EP2099911A2 (en) * 2007-01-11 2009-09-16 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
AU2014202051C1 (en) * 2007-02-06 2021-04-22 Columbia Laboratories (Bermuda) Limited Progesterone for the treatment of preterm birth
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
US20090081237A1 (en) 2007-03-12 2009-03-26 Dana-Farber Cancer Institute Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
PT2155248E (pt) 2007-04-12 2015-10-23 Brigham & Womens Hospital Direcionamento a abcb5 para tratameto do cancro
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
MX2009012482A (es) * 2007-05-17 2009-12-02 Coley Pharm Group Inc Oligonucleotidos de clase a con potencia inmunoestimuladora.
CA2690144A1 (en) 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
DK2231254T3 (da) * 2007-12-11 2014-07-21 Massachusetts Inst Technology Implanterbar lægemiddelafgivelsesindretning
JP5536666B2 (ja) 2007-12-20 2014-07-02 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 痛風の治療のための方法
LT2249757T (lt) 2008-02-04 2017-09-25 Ferring B.V. Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009108745A1 (en) * 2008-02-26 2009-09-03 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
JP2011515078A (ja) * 2008-03-01 2011-05-19 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2723648A1 (en) 2008-04-10 2009-10-15 Piyush Gupta Methods for identification and use of agents targeting cancer stem cells
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
CA2722589A1 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
US8598342B2 (en) 2008-06-12 2013-12-03 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US8729053B2 (en) * 2008-09-22 2014-05-20 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nuclear factor kappa B pathway inhibitor composition and use of same
JP5722782B2 (ja) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR20140101876A (ko) 2008-10-09 2014-08-20 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
EP2962682B1 (en) * 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
RU2512396C2 (ru) 2008-12-22 2014-04-10 Кьюбист Фармасьютикалз, Инк. Новые противобактериальные средства для лечения грамположительных инфекций
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
AR074874A1 (es) * 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
CA2759733C (en) 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP3375441A1 (en) 2009-04-30 2018-09-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Schweinfurthins and uses thereof
PL2429581T3 (pl) 2009-05-14 2016-01-29 Bayer Ip Gmbh Wzmocniona odpowiedź immunologiczna u gatunków ptaków
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
US8957075B2 (en) 2009-06-01 2015-02-17 President And Fellows Of Harvard College O-GlcNAc transferase inhibitors and uses thereof
EP3020412B1 (en) 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
US8343516B2 (en) 2009-06-26 2013-01-01 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2456432B1 (en) 2009-07-22 2024-02-28 University of Massachusetts Compositions to reduce oxidative stress
WO2011011797A2 (en) 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
PE20121495A1 (es) 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
CN102781933B (zh) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
RU2016125705A (ru) 2009-08-18 2018-12-04 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US8435795B2 (en) * 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
EP2566967B1 (en) 2010-05-04 2016-07-06 The Brigham and Women's Hospital, Inc. Cadherin-11 antagonist for the treatment of fibrosis
JP2013526572A (ja) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102010050242A1 (de) 2010-10-30 2012-05-03 Schott Ag Wirkstoffverpackung
CA2817362C (en) 2010-11-18 2018-10-23 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
LT2654785T (lt) 2010-12-22 2019-07-10 Bayer Intellectual Property Gmbh Sustiprintas galvijų imuninis atsakas
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US9114111B2 (en) 2011-01-10 2015-08-25 Allergan, Inc. Methods for sustained treatment of bladder pain and irritative voiding
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
CN103562186B (zh) 2011-01-12 2017-02-15 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
WO2012106714A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
US9434937B2 (en) 2011-03-07 2016-09-06 Accelerate Diagnostics, Inc. Rapid cell purification systems
US9296818B2 (en) 2011-03-14 2016-03-29 Marene Inga-Britt Landstrom Cleavage inhibitors of transforming growth factor beta type I receptor and uses thereof in cancer therapy
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN107188969B (zh) 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
US20140287043A1 (en) 2011-04-21 2014-09-25 Trustees Of Tufts College Compositions and methods for stabilization of active agents
WO2012167046A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2838402C (en) 2011-06-06 2019-12-03 Oak Crest Institute Of Science Drug delivery device employing wicking release window
EA026121B1 (ru) 2011-06-14 2017-03-31 Бикам Фармасьютикалз, Инк. Опсин-связывающие лиганды, композиции и способы их использования
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
US10765654B2 (en) 2011-07-19 2020-09-08 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
EP2739734A1 (en) 2011-08-03 2014-06-11 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Treatment of fibrosis using microrna-19b
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
WO2013059373A2 (en) 2011-10-17 2013-04-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
HK1201414A1 (en) 2011-10-19 2015-09-04 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
EP2944628B1 (en) 2011-11-30 2017-01-04 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9173884B2 (en) 2011-11-30 2015-11-03 Trustees Of Boston College Inhibitors of phosphodiesterase 11 (PDE11)
CA2862746A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2794657B1 (en) 2011-12-19 2017-10-11 Xoma (Us) Llc Methods for treating acne
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA3209571A1 (en) 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
CA2871490C (en) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN110812470A (zh) 2012-07-11 2020-02-21 佛蒙特大学及州农业学院 用于代谢调节的方法和组合物
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
JP2015526471A (ja) 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
US9962448B2 (en) 2012-10-04 2018-05-08 Northeastern University Compounds and methods for targeted immune system delivery
ES2718903T3 (es) 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
EP2931273A1 (en) 2012-12-12 2015-10-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Methods of treating portal hypertension
ES2872403T3 (es) 2013-03-14 2021-11-02 Childrens Medical Center Péptido Psap para el tratamiento de cánceres que expresan CD36
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
AU2014233480B2 (en) 2013-03-15 2018-08-09 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160052985A1 (en) 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
ES2982449T3 (es) 2013-06-25 2024-10-16 Walter & Eliza Hall Inst Medical Res Miméticos Smac para su uso en el tratamiento de una infección persistente por VIH
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
WO2015026813A1 (en) 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
CN105530867B (zh) * 2013-08-21 2018-11-13 传感技术股份有限公司 用于生物感测分析物的体内保护的药物洗脱
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
CA2927543C (en) 2013-10-15 2021-07-20 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
CN105992770B (zh) 2013-11-01 2021-06-25 奥斯陆大学 白蛋白的变体及其用途
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6943568B2 (ja) 2013-12-06 2021-10-06 アメリカ合衆国 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CN119775416A (zh) 2013-12-24 2025-04-08 杨森制药公司 抗vista抗体及片段
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015128461A1 (en) 2014-02-28 2015-09-03 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10314851B2 (en) 2014-03-17 2019-06-11 Massachusetts Institute Of Technology Metakaryocidal treatments
EP4154901A1 (en) 2014-03-26 2023-03-29 The Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
WO2015161230A1 (en) 2014-04-19 2015-10-22 Massachusetts Institute Of Technology Methods of reducing kinase inhibitor resistance
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
ES3007997T3 (en) 2014-05-09 2025-03-21 Univ Yale Hyperbranched polyglycerol-coated particles
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
JP2017522365A (ja) * 2014-05-30 2017-08-10 テクスタイル−ベイスド デリバリー，インコーポレイテッド 薬物送達システム及び関連する使用方法
KR102391761B1 (ko) * 2014-06-26 2022-04-27 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016029077A1 (en) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2016044383A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016046847A1 (en) 2014-09-23 2016-03-31 Council Of Scientific & Industrial Research Metal embedded hydrophilic polymer for drug delivery applications
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
CA3003397A1 (en) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
JP6944373B2 (ja) 2015-02-18 2021-10-06 ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｖｅｒｍｏｎｔ Ａｎｄ Ｓｔａｔｅ Ａｇｒｉｃｕｌｔｕｒａｌ Ｃｏｌｌｅｇｅ Ｍｃｊアゴニストおよびそれらに関する使用
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
KR20170132856A (ko) 2015-03-30 2017-12-04 액셀러레이트 다이어그노스틱스, 아이엔씨. 신속한 미생물 동정 및 항균제 감수성 시험을 위한 기기 및 시스템
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
CA3019311A1 (en) 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
JP6952685B2 (ja) 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US10633427B2 (en) 2015-06-26 2020-04-28 Prindex S.R.L. Diagnosis and therapy of multiple sclerosis
US10973912B2 (en) 2015-06-29 2021-04-13 President And Fellows Of Harvard College Treatment for myopathy
US10655126B2 (en) 2015-07-10 2020-05-19 University Of Vermont And State Agricultural College Methods and compositions to treat drug-induced diseases and conditions
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
ES2876930T3 (es) 2015-08-20 2021-11-15 Asociacion Centro De Investig Cooperativa En Biociencias Cic Biogune Métodos y composiciones para tratar enfermedades y afecciones hepáticas
US11819554B2 (en) 2015-09-17 2023-11-21 University Of Massachusetts Compositions and methods for modulating FMR1 expression
JP2019509023A (ja) 2016-01-20 2019-04-04 ザ・スクリップス・リサーチ・インスティテュート Ｒｏｒ２抗体組成物及び関連する方法
CN108848669B (zh) 2016-01-20 2022-06-07 斯克利普斯研究所 Ror1抗体组合物和相关方法
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
CA3014792A1 (en) 2016-02-16 2017-08-24 Carnegie Mellon University Compositions for enhancing targeted gene editing and methods of use thereof
US20200308590A1 (en) 2016-02-16 2020-10-01 Yale University Compositions and methods for treatment of cystic fibrosis
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP7197078B2 (ja) 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
WO2017196979A1 (en) 2016-05-10 2017-11-16 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
CA3023980A1 (en) 2016-05-16 2017-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
AU2017271606B2 (en) 2016-05-27 2024-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FLT3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018005799A1 (en) 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
US20190201414A1 (en) 2016-07-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
PH12019500191A1 (en) 2016-07-26 2022-04-11 Bayer Animal Health Gmbh Increased fertility in bovine species
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
AU2017355712B2 (en) 2016-11-07 2024-01-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics Inc métodos para quantificar proteínas inibidoras inter-alfa
EP4282411A1 (en) 2017-04-25 2023-11-29 Ischemix LLC Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
US11865093B2 (en) 2017-07-14 2024-01-09 University Of Massachusetts Methods and compositions for treating inflammation
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
WO2019030240A1 (en) 2017-08-07 2019-02-14 Nbe-Therapeutics Ag ANTIBODIES BINDING TO A LINEAR HUMAN CS1 EPITOPE
US11103460B2 (en) 2017-08-07 2021-08-31 Board Of Regents, The University Of Texas System Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
AU2017445093B2 (en) 2017-12-29 2024-09-19 Exentis Knowledge Gmbh Drug delivery system
CN111757727B (zh) 2017-12-29 2023-10-24 拉克斯顿医疗股份公司 生产药物递送系统的方法
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
CA3097403A1 (en) 2018-04-19 2019-10-24 Tvardi Therapeutics, Inc. Stat3 inhibitors
KR20210013080A (ko) 2018-05-11 2021-02-03 포르테 서브시디어리, 인크. 피부 병태의 치료를 위한 조성물
JP2021526837A (ja) 2018-06-12 2021-10-11 アンジーエックス・インコーポレーテッド 抗体−オリゴヌクレオチドコンジュゲート
EP4438618A3 (en) 2018-08-22 2025-01-01 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
WO2020072805A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020081737A1 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Compositions and methods for inducing intestinal stem cell regeneration
CA3116762A1 (en) 2018-10-19 2020-04-23 Board Of Regents, The University Of Texas System Engineered long interspersed element (line) transposons and methods of use thereof
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
PE20211977A1 (es) 2019-01-18 2021-10-05 Janssen Biotech Inc Receptores de antigenos quimericos de gprc5d y celulas que los expresan
BR112021014657A2 (pt) 2019-01-30 2021-09-21 Janssen Pharmaceutica N.V. Métodos para tratar câncer de próstata com base em subtipos moleculares
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
JP2022527569A (ja) 2019-03-21 2022-06-02 ミトセラピューティクス・エルエルシー 治療剤の標的化送達のための多価リガンドクラスター
US20220160771A1 (en) 2019-04-10 2022-05-26 Iulia Diaconu Flt3-specific chimeric antigen receptors and methods of using the same
IL288284B2 (en) 2019-05-22 2024-06-01 Massachusetts Inst Technology Circular rna compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US12077585B2 (en) 2019-07-26 2024-09-03 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
PH12022550196A1 (en) 2019-07-26 2022-11-21 Janssen Biotech Inc Anti-hk2 chimeric antigen receptor (car)
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
KR20220041934A (ko) 2019-08-16 2022-04-01 얀센 바이오테크 인코포레이티드 개선된 기능을 갖는 치료용 면역 세포 및 이의 제조 방법
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
MX2022005983A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Receptores del antígeno quimérico anti-cd79, células car-t, y usos de estos.
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
EP4107267A1 (en) 2020-02-21 2022-12-28 Mitotherapeutix LLC Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
UY40280A (es) 2020-03-13 2023-07-31 Janssen Biotech Inc Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
KR20230025534A (ko) 2020-05-08 2023-02-21 조지아뮨 엘엘씨 Akt3 조절제
JP2023527309A (ja) 2020-05-19 2023-06-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN116322776A (zh) 2020-08-03 2023-06-23 詹森生物科技公司 用于病毒治疗剂中的多向生物转运的材料和方法
WO2022081895A1 (en) 2020-10-16 2022-04-21 University Of Georgia Research Foundation, Inc. Glycoconjugates
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
CN117098781A (zh) 2021-03-24 2023-11-21 詹森生物科技公司 靶向cd22和cd79b的抗体
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
CR20230555A (es) 2021-05-28 2024-02-19 De Shaw Res Llc Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3
EP4352226A1 (en) 2021-06-07 2024-04-17 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
WO2023028451A2 (en) 2021-08-25 2023-03-02 Ibio, Inc. Anti-cd-25 antibody
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
CR20240196A (es) 2021-11-16 2024-07-08 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt)
KR20240111795A (ko) 2021-11-29 2024-07-17 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
AU2022417615A1 (en) 2021-12-23 2024-06-27 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물
CN120092091A (zh) 2022-05-30 2025-06-03 上海环码生物医药有限公司 合成的环状rna组合物及其使用方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024039376A1 (en) 2022-08-18 2024-02-22 Elanco Us Inc. Method for improving growth performance in feedlot cattle
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202425959A (zh) 2022-11-08 2024-07-01 美商歐納醫療公司 遞送多核苷酸的脂質及奈米顆粒組合物
WO2024112515A1 (en) 2022-11-21 2024-05-30 Northeastern University Click chemistry ligand
AU2023404700A1 (en) 2022-12-02 2025-07-10 Shanghai Argo Biopharmaceutical Co., Ltd. Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom
AU2023398825A1 (en) 2022-12-15 2025-06-26 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2024244071A1 (en) 2023-04-06 2025-10-30 Shanghai Argo Biopharmaceutical Co., Ltd. Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025059689A1 (en) 2023-09-16 2025-03-20 University Of Massachusetts Compositions and methods for promoting the generation of pharyngeal foregut endoderm and its derivatives
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025240947A1 (en) 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
NL297357A (enExample) * 1962-08-31
US3518340A (en) * 1968-04-15 1970-06-30 Dow Corning Method of forming silicone rubber drug carriers
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368962A1 (fr) * 1976-11-02 1978-05-26 Merck Patent Gmbh Pansement anti-bacterien et son procede de fabrication
FR2397190A1 (fr) * 1977-07-12 1979-02-09 Alza Corp Moyen pour l'administration de medicaments a travers la peau
EP0062682A4 (en) * 1980-10-20 1983-09-20 Nichiban Kk ADHESIVE PREPARATION FOR HEART DISEASES AND PROCESS FOR PREPARING THE SAME.
FR2512651A1 (fr) * 1981-06-24 1983-03-18 Pere Lahaille Jeanne Produits anti-rides
FR2534140A1 (fr) * 1982-10-12 1984-04-13 Fournier Laboratoires Nouveau dispositif pour l'administration percutanee de medicaments
EP0107575A1 (fr) * 1982-10-12 1984-05-02 Laboratoires Fournier S.A. Dispositif pour l'administration percutanée de principe actif
FR2538247A1 (fr) * 1982-12-23 1984-06-29 Pere Lahaille Jeanne Pastille anti-rides et/ou traitant la peau
WO1984002466A1 (fr) * 1982-12-23 1984-07-05 Pere Lahaille Jeanne Pastille anti-rides et/ou traitant la peau
FR2548021A1 (fr) * 1983-06-29 1985-01-04 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
EP0151989A3 (en) * 1984-01-28 1986-10-08 Roshdy Dr. Ismail Means for the treatment of cardiac diseases
FR2581314A1 (fr) * 1985-05-03 1986-11-07 Alza Corp Dispositif medical pour l'administration transdermique de medicaments fortement ionises insolubles dans les corps gras
EP0262422A1 (en) * 1986-09-01 1988-04-06 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
EP0274863A3 (en) * 1987-01-09 1989-11-02 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
US5322695A (en) * 1987-01-09 1994-06-21 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
EP0344840A3 (en) * 1988-06-02 1990-02-21 Merck & Co. Inc. Transdermal delivery systems
WO1996031201A1 (en) * 1995-04-06 1996-10-10 Janssen Pharmaceutica N.V. Rate-controlled transdermal administration of risperidone

Also Published As

Publication number Publication date
DE2135533C3 (de) 1981-02-12
US3854480A (en) 1974-12-17
DE2135533A1 (de) 1973-02-01
CH574742A5 (enExample) 1976-04-30
FR2143564B1 (enExample) 1974-04-05
DE2135533B2 (de) 1980-06-04

Similar Documents

Publication Publication Date Title
FR2143564A1 (en) Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates
US3598122A (en) Bandage for administering drugs
US3742951A (en) Bandage for controlled release of vasodilators
KR900007500B1 (ko) 작용제의 개량된 투약기
US3731683A (en) Bandage for the controlled metering of topical drugs to the skin
ES8605160A1 (es) Mejoras en la fabricacion de preparados del tipo de absorcion percutanea y procedimiento correspondiente
DE69121881D1 (de) Hautelektrodenaufbau und dazugehöriges gerät zur transdermalen verabreichung von heilmitteln
KR890701164A (ko) 피부침투성 치료 시스템
AU622775B2 (en) A plaster used as therapeutic system for the administration of active substances to the skin, which exhibits a graduated active substance release, process for the production of the plaster and the use thereof
KR870006906A (ko) 피부투과식 약물투여장치
DE3161605D1 (en) Therapeutic system for administering drugs to the skin
ATE188866T1 (de) Transdermales arzneimittelverabreichungssystem
JPS57185870A (en) Applicator of pharmacologically active drug, production and use thereof
RU98102774A (ru) Транскорнеальная система высвобождения лекарства
MY103355A (en) Active substance-containing plaster of the controlled administration of active substances to the skin, the use thereof and a process for the controlled administration of active substances to the skin
ATE63059T1 (de) Vorrichtung mit zwei schichten zur freisetzung von arzneimitteln.
JPS61106507A (ja) 経皮的および経粘膜的渦式発泡体デバイスと製造方法
GB1519149A (en) Devices for administering medicaments
ES402773A1 (es) Dispositivo para la administracion de sustancias activas a animales.
ES444552A1 (es) Un sistema terapeutico en forma de un aposito para adminis- tracion de escopolamina base.
JPS6452457A (en) Multiple unit admistration system
GB1361289A (en) Bandage for administering drugs
ES8704740A1 (es) Procedimiento para preparar un producto farmaceutico para la entrega controlada de sustancias activas a la piel,preferentemente en forma de un emplasto
JPH0693921B2 (ja) 段階的な薬物放出を呈する皮膚経由医療薬
ES406464A1 (es) Dispositivo ocular bioerosionable para la administracion continua y controlada de una dosificacion predeterminada de droga al ojo.